Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulationESPEJO, Carmen; MONTALBAN, Xavier.Clinical immunology (Orlando, Fla. Print). 2012, Vol 142, Num 1, pp 84-92, issn 1521-6616, 9 p.Article

Sustained-Release Fampridine for Symptomatic Treatment of Multiple SclerosisKORENKE, Anne R; RIVEY, Michael P; ALLINGTON, Douglas R et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 10, pp 1458-1465, issn 1060-0280, 8 p.Article

Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging studyGOODMAN, A. D; COHEN, J. A; CROSS, A et al.Multiple sclerosis. 2007, Vol 13, Num 3, pp 357-368, issn 1352-4585, 12 p.Article

Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryHAYES, Keith C; POTTER, Patrick J; HANSEBOUT, Robert R et al.Clinical neuropharmacology. 2003, Vol 26, Num 4, pp 185-192, issn 0362-5664, 8 p.Article

Steady-State Pharmacokinetics and Tolerability of Orally Administered Fampridine Sustained-Release 10-mg Tablets in Patients With Multiple Sclerosis: A 2-Week, Open-Label, Follow-Up StudyVOLLMER, Timothy; BLIGHT, Andrew R; HENNEY, Herbert R et al.Clinical therapeutics. 2009, Vol 31, Num 10, pp 2215-2223, issn 0149-2918, 9 p.Article

Pharmacokinetics and Tolerability of Single Escalating Doses of Fampridine Sustained-Release Tablets in Patients With Multiple Sclerosis: A Phase I-II, Open-Label TrialVOLLMER, Timothy; HENNEY, Herbert R.Clinical therapeutics. 2009, Vol 31, Num 10, pp 2206-2214, issn 0149-2918, 9 p.Article